Posted by Michael Wonder on 10 May 2021
Positive CHMP opinion for self-administered Crysvita
10 May 2021 - The EMA's CHMP has recommended Kyowa Kirin’s Crysvita for a new self-administration option to treat the rare metabolic bone disease X-linked hypophosphataemia (XLH).
XLH is a rare, genetic disease that causes bone, muscle and joint abnormalities. Although the condition is not life-threatening, it may reduce an individual’s quality of life with a life-long and progressive burden.
Currently, Crysvita (burosumab) is administered by subcutaneous injection, and will still need to be initiated by an experienced physician if the new self-administration option is ultimately approved.
